In Stock Cell Lines
The PDK4 Knockout HK-2 Cell Line is a CRISPR/Cas9-edited human proximal tubule epithelial cell line with targeted disruption of pyruvate dehydrogenase kinase 4 (PDK4). PDK4 regulates glucose and fatty acid metabolism by inhibiting the pyruvate dehydrogenase complex, integrating signals from upstream regulators such as PPAR??, FOXO1, and insulin, and influencing downstream targets like PDHA1 and acetyl-CoA production. This model enables investigation of metabolic reprogramming in kidney proximal tubule cells, with applications in diabetes, obesity, metabolic syndrome, cardiovascular disease, and cancer research. It supports functional studies including glucose uptake, fatty acid oxidation, mitochondrial respiration, and insulin sensitivity assays, providing a physiologically relevant platform for drug testing and signaling pathway analysis.
FDFT1 Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG18136
CSNK1E Knockout HT29 Polyclonal Cells
Cat. No. ARG13866
HMGB2 Knockout Hela Polyclonal Cells
Cat. No. ARG37187
CHST3 Knockout MES-OV Polyclonal Cells
Cat. No. ARG6483
CIC Knockout AGS Polyclonal Cells
Cat. No. ARG3119
Mouse Thyroid Epithelial Cell Medium
Cat. No. ARM0515
The PDK4 Knockout HK-2 Cell Line is a CRISPR/Cas9-edited human proximal tubule epithelial cell line designed for loss-of-function studies of pyruvate dehydrogenase kinase 4 (PDK4). This genetically engineered model is produced through targeted disruption of the PDK4 gene in the immortalized HK-2 cell line, generating a stable knockout cell line suitable for metabolic and signaling research. The knockout cell line serves as a powerful tool to investigate PDK4-dependent regulation of glucose and fatty acid metabolism, particularly in the context of kidney proximal tubule pathophysiology, metabolic disorders, and cancer metabolism.
HK-2 cells are human kidney proximal tubule epithelial cells immortalized with HPV-16 E6/E7, retaining a differentiated proximal tubular phenotype. This host cell line maintains critical functions of the proximal tubule, including reabsorption of glucose, amino acids, and ions, secretion of organic cations and anions, and pH regulation. The HK-2 background provides a physiologically relevant platform to examine metabolic reprogramming and nutrient-sensing mechanisms in renal epithelia, making it an ideal system for studying PDK4’s impact on tubular metabolism and injury response.
PDK4 functions as a key metabolic regulator by phosphorylating and inactivating the pyruvate dehydrogenase complex (PDC), thereby shunting pyruvate away from the tricarboxylic acid (TCA) cycle and promoting fatty acid oxidation. The PDK4 signaling network integrates inputs from upstream transcriptional regulators including PPAR??, PPAR??, PPAR??, FOXO1, HIF-1??, glucocorticoids, and PGC-1??, as well as kinase-mediated signals through insulin/AMPK pathways. Downstream, PDK4 directly targets the E1?? subunit of PDC (PDHA1), modulating acetyl-CoA production and influencing TCA cycle activity. PDK4 activity also connects to CPT1a-mediated fatty acid transport and interacts indirectly with LKB1, positioning it at the intersection of insulin, PPAR, AMPK, and HIF-1 signaling cascades.
In HK-2 cells, PDK4 knockout is expected to shift cellular metabolism toward glycolysis by relieving PDC inhibition, which may alter ATP production, redox balance, and biosynthetic intermediate availability. This model provides a unique opportunity to dissect how proximal tubule cells adapt to nutrient stress, such as high glucose or lipid overload, and to explore PDK4’s role in diabetic kidney disease, obesity-related renal lipotoxicity, and metabolic syndrome. Furthermore, the knockout line can be used to study the interplay between PDK4 and upstream regulators like insulin and AMPK in a kidney-specific context, revealing potential therapeutic targets for metabolic and fibrotic kidney diseases.
The PDK4 Knockout HK-2 Cell Line supports a wide range of functional assays, including Western blotting for PDK4 and phosphorylated PDHA1, glucose uptake and fatty acid oxidation measurements, and mitochondrial respiration analysis via Seahorse technology. It is also suited for RT-qPCR profiling of metabolic genes, insulin sensitivity assessments, and cell viability tests under metabolic stress conditions. This knockout cell line is an essential resource for investigators exploring metabolic reprogramming in diabetes, obesity, cardiovascular disease, and cancer, as well as for preclinical drug testing targeting metabolic pathways. For further information, customization options, or technical support, please contact Ascent Research.